Abstract 350P
Background
Immune checkpoint inhibitors (ICI) have demonstrated improvement in overall survival across a range of tumor types. However, ICI therapy is associated with severe immune related adverse events (irAEs) including inflammatory arthritis. Here, we report our experience for rheumatological irAEs in patients with and without pre-existing auto-immune disease (AID).
Methods
Data was collected retrospectively for 15 patients identified as having rheumatological irAEs secondary to ICI therapy in our center between 2015-2019. We identified three patients with pre-existing AID.
Results
The mean age of the cohort was 66 years.The commonest tumour types were melanoma (73%) and NSCLC (27%). In the group without AID, (n=12), 7 patients developed inflammatory arthritis (IA). Two patients with PMR like syndrome depicted typical clinical phenotypes supported by raised inflammatory markers. The SICCA syndrome patient had biopsy proven lichenoid drug eruption and feature of xerostomia. One patient had synovial aspiration proved OA exacerbation treated with intra-articular corticosteroid injection, ceasing ICI. One patient developed grade 3 immune mediated myositis 12 days after commencing nivolumab. Muscle biopsy showed active inflammatory myopathy and lymphocytic vasculitis. Median time to any rheumatologic irAEs was 9.8 weeks. Treatment was withheld temporarily in patient and it was stopped permanently in 2 patients. All patients had high doses of glucocorticoids that led to significant, moderate and minimal improvement in 2, 8 and 2 patients, respectively. Additionally, 3 patients needed other disease modifying anti-rheumatoid drugs (DMARDs). In cohort with pre-existing AID (n=3), only patient with rheumatoid arthritis (RA), had flare of RA after 7 weeks of initiating ICI therapy. ICI therapy was withheld and had resolution of symptoms with steroids.
Conclusions
Rheumatic irAEs are serious and less understood adverse events secondary to ICI therapy requiring steroids and additional immunosuppressive therapy. Future studies should aim at defining the type of rheumatologic irAEs experienced in trials patients and response to steroids +/- DMARDs. A mutli-disciplinary approach is recommended.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Azim Khan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session